久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Sanofi’s RSV treatment nirsevimab awarded PIM pharmatimes
    January 22, 2021
    Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the prevention of respiratory syncytial virus (RSV) associated lower respiratory ...
  • Nirsevimab gets Promising Innovative Medicine Designation from MHRA expresspharma
    January 19, 2021
    Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus (RSV) infections in healthy late preterm, term and high-risk infants.
  • Akcea’s rare lipid disorder drug wins PIM status pharmatimes
    October 11, 2017
    Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome , a rare genetic lipid disorder.
PharmaSources Customer Service